Supplemental New Drug Application For Lubiprostone To Treat IBS With Constipation Submitted By Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).
